Status: Recruiting
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.
Participants needed: 11
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 15, 2026Locations: 1
Eligibility criteria
Patients older than 18 years of age with histologically proven squamous cell car... [+6]
Patients who have undergone resection of primary disease. [+10]